List of Excipients in Branded Drug CAPLYTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
REMEDYREPACK INC	CAPLYTA	lumateperone	70518-3497	CROSCARMELLOSE SODIUM	2040-12-10
REMEDYREPACK INC	CAPLYTA	lumateperone	70518-3497	GELATIN	2040-12-10
REMEDYREPACK INC	CAPLYTA	lumateperone	70518-3497	MAGNESIUM STEARATE	2040-12-10

CAPLYTA Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

CAPLYTA, Intra-Cellular Therapies’ lumateperone product, is an oral hard-gelatin capsule with a conventional solid-dose excipient platform. The commercial opportunity is not primarily a novel-excipient play. It is a risk-managed opportunity in generic-ready formulation development, capsule-shell differentiation, supply security, taste and stability control, and potential reformulation into longer-acting or patient-friendly delivery systems.

CAPLYTA generated approximately $544.6 million in U.S. net product sales in 2024, supported by approvals for schizophrenia, bipolar depression, and adjunctive treatment of major depressive disorder.[1] The product’s active pharmaceutical ingredient is lumateperone tosylate. Because CAPLYTA is a small-molecule drug, biosimilar competition is not relevant. The principal future threat is an Abbreviated New Drug Application, or ANDA, supported by Paragraph IV patent challenges.

What excipients are used in CAPLYTA capsules?

CAPLYTA uses standard oral solid-dose excipients rather than a publicly identified proprietary delivery technology.

The FDA prescribing information identifies inactive ingredients that include mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate. The hard capsule shell contains gelatin and colorants that vary by strength.[2]

Excipient or component	Likely formulation function	Commercial relevance
Mannitol	Diluent; contributes to powder handling and mouthfeel	Multiple qualified suppliers; potential cost and supply advantage
Microcrystalline cellulose	Binder and diluent	Common generic platform material
Croscarmellose sodium	Superdisintegrant	Supports capsule disintegration and dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Important for powder flow and blend uniformity
Talc	Processing aid and anti-adherent	Requires supplier qualification and impurity controls
Magnesium stearate	Lubricant	Excessive use can affect dissolution and blend uniformity
Gelatin	Capsule shell	Creates animal-origin, vegetarian, and supply-chain considerations
Capsule colorants	Product identification and strength differentiation	Creates opportunities for shell redesign in generic products

The excipient profile indicates a conventional immediate-release capsule. The key technical requirements are blend uniformity, rapid and reproducible dissolution, chemical stability, and control of lumateperone content uniformity at each marketed strength.

How does CAPLYTA’s excipient strategy affect generic development?

A generic developer can likely use the same or functionally equivalent excipients, subject to FDA inactive-ingredient limits, product-specific guidance, and comparative dissolution results. The formulation is unlikely to create a high barrier solely through excipient selection.

The principal development risks are:

1. Matching dissolution across strengths.
2. Controlling lumateperone distribution in a low-dose capsule.
3. Avoiding lubricant-related dissolution retardation.
4. Demonstrating stability under accelerated and long-term conditions.
5. Qualifying capsule-shell materials and colorants.
6. Establishing bioequivalence against the reference product.

The FDA’s product-specific guidance for lumateperone capsules is the central regulatory document for ANDA planning. A developer should treat the reference listed drug’s formulation as a performance target, not necessarily as an ingredient-by-ingredient template.[3]

Which excipient attributes matter most?

Particle-size distribution, bulk density, moisture content, and flowability are likely to have greater impact than the commercial identity of the supplier. For a low-dose drug product, geometric dilution and segregation control are especially important.

The highest-value excipient controls are:

• Narrow particle-size distributions for mannitol and microcrystalline cellulose.
• Consistent moisture levels in superdisintegrant and filler materials.
• Low-variability colloidal silicon dioxide for flow control.
• Controlled magnesium stearate surface area and blending time.
• Capsule-shell dimensional consistency.
• Low extractables and leachables from packaging and shell components.

A supplier with a strong change-control system can create more value than a supplier offering a nominally differentiated excipient.

What commercial opportunities exist in CAPLYTA excipients?

The commercial opportunity divides into four areas: generic formulation supply, specialty excipients, capsule-shell systems, and lifecycle reformulation.

Generic formulation supply

The most immediate opportunity is supplying excipients for future lumateperone ANDA products. The opportunity favors high-volume, compendial materials with reliable regulatory documentation rather than highly novel excipients.

Potential suppliers can differentiate through:

• Multi-site manufacturing.
• DMF support and regulatory packages.
• Low-nitrosamine and low-elemental-impurity profiles.
• Fast change-notification procedures.
• Small-volume supply for early clinical and pilot batches.
• Technical support for dissolution and content-uniformity failures.

Generic manufacturers will likely seek a formulation that is simple to manufacture and avoids unnecessary excipient changes. A supplier that can provide a complete, qualified excipient package may reduce development time.

Specialty excipients

A specialty excipient could create value if it improves one of four performance attributes:

• Lumateperone dissolution.
• Blend uniformity.
• Moisture stability.
• Capsule-fill consistency.

Examples include engineered mannitol, co-processed cellulose-based excipients, or directly compressible materials adapted for capsule filling. The commercial case is stronger if the excipient is already accepted in oral solid-dose products and has an established regulatory history.

A novel excipient would face a higher barrier. Its developer would need to address toxicology, regulatory acceptance, supply scale, and customer willingness to accept formulation-specific risk. CAPLYTA alone is unlikely to justify a major novel-excipient investment.

Capsule-shell systems

Capsule shells offer a practical differentiation route. Opportunities include:

• Vegetarian hydroxypropyl methylcellulose shells.
• Titanium-dioxide-free opaque shells.
• Improved moisture-barrier capsules.
• Tamper-evident or serialization-compatible shells.
• Color systems that simplify strength identification.
• Shells optimized for automated high-speed filling.

A shell change must preserve dissolution, stability, appearance, and regulatory comparability. For a generic product, capsule-shell substitution may be commercially attractive but can create additional analytical and regulatory work.

Lifecycle reformulation

The innovator’s strongest excipient opportunity is lifecycle management. Possible approaches include:

• Lower-strength capsules for titration.
• Higher-strength capsules that reduce pill burden.
• Orally disintegrating tablets.
• Sprinkle or suspension formulations for patients with swallowing difficulty.
• Long-acting injectable formulations.
• Fixed-dose combinations with other psychiatric medicines.

Each approach would need to establish clinical and commercial value. An orally disintegrating formulation could address adherence and swallowing problems, while a long-acting formulation could materially expand the product’s competitive position. Neither opportunity is created by ordinary excipient substitution alone.

What patents protect CAPLYTA’s formulation and excipients?

CAPLYTA’s principal intellectual-property position is expected to center on lumateperone composition, therapeutic use, and product-related claims rather than on individual commodity excipients.

IP category	Relevance to CAPLYTA	Generic risk
Lumateperone composition patents	Protect the active molecule or defined chemical forms	High before expiration or successful invalidity challenge
Method-of-use patents	Cover schizophrenia, bipolar depression, or depressive-disorder treatment methods	Relevant to labeling and carve-out strategy
Formulation patents	May cover capsule composition, dosage range, stability, or release performance	Potential Paragraph IV exposure
Manufacturing patents	May cover preparation of lumateperone or drug-product processing	More relevant to API and supply chain
Excipient patents	Usually protect a specific engineered material or formulation architecture	Likely narrow unless tied to product performance
Capsule-shell patents	May protect shell composition or barrier properties	Usually avoidable through design-around

Commodity excipients such as mannitol, microcrystalline cellulose, croscarmellose sodium, silica, talc, and magnesium stearate are not, by themselves, likely to block generic entry. Patent risk would arise from a claimed combination, a defined particle-size range, a co-processed material, or a performance limitation.

The Orange Book status of CAPLYTA should be evaluated by reviewing the current FDA listing for lumateperone capsules, including patent numbers, expiration dates, pediatric exclusivity, and any listed use codes.[4] Patent claims should be separated into three groups:

1. Claims that can block all generic products.
2. Claims that can be avoided through a Section viii labeling carve-out.
3. Claims that require a Paragraph IV certification and litigation risk assessment.

When does CAPLYTA lose exclusivity?

CAPLYTA exclusivity is governed by separate regulatory and patent timelines.

FDA regulatory exclusivity

CAPLYTA received FDA approval in December 2019 for schizophrenia. It later received approval for depressive episodes associated with bipolar disorder and, in December 2024, as adjunctive treatment for major depressive disorder.[5,6]

New indication approvals may provide regulatory exclusivity for the approved use, but they do not necessarily prevent an ANDA applicant from entering with an unprotected indication. A generic applicant may use a Section viii statement to omit patented uses if the remaining label supports approval.

Patent expiration

The relevant date is not the date of the original NDA approval. It is the expiration date of each Orange Book-listed patent, adjusted for patent-term extension, pediatric exclusivity, terminal disclaimers, and litigation outcomes.

An accurate CAPLYTA entry forecast therefore requires a patent-by-patent review. A headline expiry date can be misleading if:

• A formulation patent expires later than the compound patent.
• A method-of-use patent supports only one indication.
• Pediatric exclusivity adds six months.
• A Paragraph IV settlement creates an agreed launch date.
• A court invalidates or narrows a listed patent.

Which companies are challenging CAPLYTA patents?

Publicly confirmed challengers should be identified from FDA Paragraph IV notices, federal court dockets, and the Orange Book. A generic manufacturer may challenge CAPLYTA patents without immediately launching. It may also file an ANDA with a Paragraph III certification, a Section viii statement, or a Paragraph IV certification depending on the patent portfolio.

The first-filer economics can be material if the ANDA qualifies for 180-day generic exclusivity. The commercial value of that position depends on:

• The number of additional ANDAs filed.
• Whether the relevant patent is found valid and infringed.
• Whether the settlement permits an early launch.
• Whether the generic label excludes patented indications.
• Whether the innovator has authorized-generic plans.

Without a verified current litigation docket, no specific challenger or settlement should be treated as confirmed.

What patent litigation and settlement risks affect CAPLYTA?

CAPLYTA litigation can arise in three principal forms:

Paragraph IV litigation

A Paragraph IV notice alleging invalidity, unenforceability, or non-infringement can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[7]

Method-of-use disputes

Method patents covering adjunctive major depressive disorder treatment or other indications may support litigation even if a generic can enter for schizophrenia or bipolar depression. The practical issue is whether the proposed label, promotional conduct, and prescribing patterns create induced-infringement exposure.

Settlement agreements

A settlement may establish:

• An agreed generic launch date.
• Restrictions on authorized-generic competition.
• A license to selected patents.
• Payment or commercial terms.
• A launch contingent on patent invalidation.
• Limits on which indications the generic may market.

Settlement analysis requires the actual agreement, FTC review, court filings, and FDA approval status. No settlement should be assumed from an ANDA filing alone.

Is biosimilar risk relevant to CAPLYTA?

No. CAPLYTA contains the small molecule lumateperone tosylate, not a biologic. The relevant competitors are generic capsule manufacturers and potential branded reformulations.

Biosimilar development timelines, interchangeability, and biologics exclusivity do not apply. The competitive analysis should instead focus on ANDA approval, patent litigation, manufacturing capacity, and the ability to launch a product with a compliant label.

How strong is the CAPLYTA patent estate?

The estate should be rated in layers rather than with a single score.

Layer	Indicative strength	Strategic implication
Core compound protection	Potentially strong if claims remain valid and unexpired	Can delay broad generic entry
Method-of-use protection	Moderate because carve-outs may be available	May protect selected revenue segments
Formulation protection	Depends on claim specificity and design-around options	Important for capsule composition and stability
Manufacturing protection	Variable; often avoidable through alternate processes	More relevant to API suppliers
Excipient protection	Usually narrow for conventional excipients	Limited standalone blocking power

The strongest commercial position exists when the innovator combines valid compound claims with later-expiring formulation or use patents. The weakest position exists when later patents cover only conventional excipients or narrow process parameters that a generic can readily avoid.

What generic launch scenarios exist for CAPLYTA?

Scenario 1: Delayed broad launch

A generic applicant challenges key patents, loses or settles, and launches after the last effective patent or agreed settlement date. This produces the largest erosion risk because all major indications may become exposed.

Scenario 2: Carved-out launch

A generic launches with patented indications removed from its label. Revenue erosion is initially concentrated in non-protected indications. Pharmacy substitution and prescriber behavior determine whether the carve-out remains commercially meaningful.

Scenario 3: Authorized generic competition

The innovator or its commercial partner launches an authorized generic. This can reduce the first-filer’s price advantage and preserve part of the franchise economics.

Scenario 4: Reformulated branded product

A new dosage form or delivery system launches before generic entry. The success of this strategy depends on clinical differentiation, reimbursement, adherence benefits, and the strength of the reformulated product’s patent estate.

How does CAPLYTA compare with competing antipsychotic products?

CAPLYTA competes with generic quetiapine, generic lurasidone, cariprazine, brexpiprazole, and other branded or generic atypical antipsychotics. Its commercial differentiation includes its approved use across schizophrenia, bipolar depression, and adjunctive major depressive disorder, as well as its once-daily capsule presentation.[2,5,6]

From an excipient perspective, CAPLYTA is less differentiated than products using extended-release matrices, transdermal systems, long-acting injectables, or complex multiparticulate delivery. Its supply chain should therefore compete on quality, cost, stability, and regulatory execution rather than on a proprietary excipient story.

What is the revenue exposure to excipient and generic risk?

The 2024 CAPLYTA revenue base creates meaningful exposure to formulation and supply-chain decisions. A manufacturing interruption involving a single critical excipient, capsule shell, or API source could affect product availability across multiple strengths.

The highest-priority controls are:

• Dual sourcing for mannitol, microcrystalline cellulose, and capsule shells.
• Validated alternatives for superdisintegrant and lubricant grades.
• Tight supplier change-control provisions.
• Finished-product dissolution monitoring after excipient changes.
• Inventory protection for colorants and gelatin shells.
• Separate qualification of vegetarian-shell alternatives.
• Packaging studies for moisture and oxygen sensitivity.

Generic entry is likely to cause a sharper revenue decline than excipient substitution. Excipient strategy should therefore support two objectives: preserve branded supply continuity and reduce the technical cost of generic development for prospective licensees or contract manufacturers.

Key Takeaways

• CAPLYTA uses a conventional hard-gelatin capsule excipient platform.
• The main listed excipients are mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate.
• Conventional excipients are unlikely to create a durable standalone patent barrier.
• The strongest commercial opportunities are generic excipient supply, qualified alternate sources, specialty flow and dissolution materials, capsule-shell systems, and lifecycle reformulation.
• CAPLYTA has no biosimilar risk because lumateperone is a small molecule.
• Generic exposure depends on Orange Book patents, Paragraph IV challenges, method-of-use carve-outs, and settlement terms.
• The highest-value reformulation opportunities are orally disintegrating, sprinkle, higher-strength, and long-acting presentations.
• Supplier differentiation should focus on regulatory documentation, change control, low impurity risk, and manufacturing reliability.

FAQs

Can a generic CAPLYTA use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the formulation complies with FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, stability, and acceptable dissolution performance.

Are CAPLYTA’s capsule colors patent-protected?

Capsule colors may be protected through trademark, trade dress, or product-identification rights, but color selection alone is unlikely to prevent a generic from using a legally distinct appearance.

Is a vegetarian capsule a meaningful CAPLYTA lifecycle opportunity?

It can be. A vegetarian shell may improve patient acceptability and supply flexibility, but it must maintain dissolution, stability, fill performance, and regulatory comparability.

Could an excipient change trigger a new CAPLYTA FDA approval?

For the branded product, a material formulation change may require a supplemental NDA, depending on the change and its effect on product quality. For a generic, the change is addressed through the ANDA development and regulatory pathway.

Does CAPLYTA have a manufacturing patent separate from its drug patent?

Potentially. Pharmaceutical products often have separate patent families covering the active compound, therapeutic use, formulation, or manufacturing process. The commercial significance depends on the specific claim scope, expiration date, and availability of design-around processes.

References

1. Intra-Cellular Therapies, Inc. (2025). 2024 annual report on Form 10-K. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2024). CAPLYTA (lumateperone) prescribing information. Intra-Cellular Therapies, Inc.

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2019). FDA approves new treatment for schizophrenia: CAPLYTA. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2024). FDA approves lumateperone as adjunctive therapy for major depressive disorder. Center for Drug Evaluation and Research.

7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).